Activity-based proteomic and metabolomic approaches for understanding metabolism

Current Opinion in Biotechnology

Volumn 28, Issue , 2014, Pages 116-126

  Hunerdosse, Devon ^a   Nomura, Daniel K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVITY-BASED; ACTIVITY-BASED PROTEIN PROFILING; BIOCHEMICAL PATHWAY; CHEMICAL PROBES; FUNCTIONAL STATE; HUMAN PATHOLOGIES; METABOLIC PATHWAYS; METABOLOMICS;

DISEASES; PHYSIOLOGY;

METABOLISM;

CASPASE; CYSTEINE PROTEINASE; ENZYME INHIBITOR; GLYCOSIDASE; HYDROLASE; SERINE HYDROLASE; UNCLASSIFIED DRUG;

ACTIVITY BASED PROTEIN PROFILING; ENZYME ACTIVITY; ENZYME STRUCTURE; HUMAN; MASS SPECTROMETRY; METABOLOMICS; NANOSTRUCTURE INITIATOR MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; REVIEW;

ANIMALS; ENZYME INHIBITORS; ENZYMES; HUMANS; METABOLIC NETWORKS AND PATHWAYS; METABOLOMICS; NEOPLASMS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEOME; PROTEOMICS;

EID: 84896844661     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2014.02.001     Document Type: Review

References (70)

1. Simon G.M., Cravatt B.F. Challenges for the 'chemical-systems' biologist. Nat Chem Biol 2008, 4:639-642.
2. Simon G.M., Cravatt B.F. Activity-based proteomics of enzyme superfamilies: serine hydrolases as a case study. J Biol Chem 2010, 285:11051-11055.
3. Edwards A.M., Isserlin R., Bader G.D., Frye S.V., Willson T.M., Yu F.H. Too many roads not taken. Nature 2011, 470:163-165.
4. Evans M.J., Cravatt B.F. Mechanism-based profiling of enzyme families. Chem Rev 2006, 106:3279-3301.
5. Nomura D.K., Dix M.M., Cravatt B.F. Activity-based protein profiling for biochemical pathway discovery in cancer. Nat Rev Cancer 2010, 10:630-638.
6. Moellering R.E., Cravatt B.F. How chemoproteomics can enable drug discovery and development. Chem Biol 2012, 19:11-22.
7. Jessani N., Niessen S., Wei B.Q., Nicolau M., Humphrey M., Ji Y., Han W., Noh D.Y., Yates J.R., Jeffrey S.S., Cravatt B.F. A streamlined platform for high-content functional proteomics of primary human specimens. Nat Methods 2005, 2:691-697.
8. Nomura D.K., Long J.Z., Niessen S., Hoover H.S., Ng S.W., Cravatt B.F. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010, 140:49-61.
9. Nomura D.K., Lombardi D.P., Chang J.W., Niessen S., Ward A.M., Long J.Z., Hoover H.H., Cravatt B.F. Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chem Biol 2011, 18:846-856.
10. Jessani N., Liu Y., Humphrey M., Cravatt B.F. Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc Natl Acad Sci USA 2002, 99:10335-10340.
11. Jessani N., Humphrey M., McDonald W.H., Niessen S., Masuda K., Gangadharan B., Yates J.R., Mueller B.M., Cravatt B.F. Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo. Proc Natl Acad Sci USA 2004, 101:13756-13761.
12. Madsen M.A., Deryugina E.I., Niessen S., Cravatt B.F., Quigley J.P. Activity-based protein profiling implicates urokinase activation as a key step in human fibrosarcoma intravasation. J Biol Chem 2006, 281:15997-16005.
13. Shields D.J., Niessen S., Murphy E.A., Mielgo A., Desgrosellier J.S., Lau S.K., Barnes L.A., Lesperance J., Bouvet M., Tarin D., Cravatt B.F., Cheresh D.A. RBBP9: a tumor-associated serine hydrolase activity required for pancreatic neoplasia. Proc Natl Acad Sci USA 2010, 107:2189-2194.
14. Blais D.R., Lyn R.K., Joyce M.A., Rouleau Y., Steenbergen R., Barsby N., Zhu L.F., Pegoraro A.F., Stolow A., Tyrrell D.L., Pezacki J.P. Activity-based protein profiling identifies a host enzyme, carboxylesterase 1, which is differentially active during hepatitis C virus replication. J Biol Chem 2010, 285:25602-25612.
15. Singaravelu R., Blais D.R., McKay C.S., Pezacki J.P. Activity-based protein profiling of the hepatitis C virus replication in Huh-7 hepatoma cells using a non-directed active site probe. Proteome Sci 2010, 8:5.
16. Wiedner S.D., Ansong C., Webb-Robertson B.J., Pederson L.M., Fortuin S., Hofstad B.A., Shukla A.K., Panisko E.A., Smith R.D., Wright A.T. Disparate proteome responses of pathogenic and nonpathogenic aspergilli to human serum measured by activity-based protein profiling (ABPP). Mol Cell Proteomics: MCP 2013, 12:1791-1805.
17. Chauvigne-Hines L.M., Anderson L.N., Weaver H.M., Brown J.N., Koech P.K., Nicora C.D., Hofstad B.A., Smith R.D., Wilkins M.J., Callister S.J., Wright A.T. Suite of activity-based probes for cellulose-degrading enzymes. J Am Chem Soc 2012, 134:20521-20532.
18. Sadler N.C., Angel T.E., Lewis M.P., Pederson L.M., Chauvigne-Hines L.M., Wiedner S.D., Zink E.M., Smith R.D., Wright A.T. Activity-based protein profiling reveals mitochondrial oxidative enzyme impairment and restoration in diet-induced obese mice. PLoS One 2012, 7:e47996.
19. Barglow K.T., Cravatt B.F. Discovering disease-associated enzymes by proteome reactivity profiling. Chem Biol 2004, 11:1523-1531.
20. Berger A.B., Vitorino P.M., Bogyo M. Activity-based protein profiling: applications to biomarker discovery, in vivo imaging and drug discovery. Am J Pharmacogenomics 2004, 4:371-381.
21. Blum G., von Degenfeld G., Merchant M.J., Blau H.M., Bogyo M. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat Chem Biol 2007, 3:668-677.
22. Edgington L.E., Berger A.B., Blum G., Albrow V.E., Paulick M.G., Lineberry N., Bogyo M. Noninvasive optical imaging of apoptosis by caspase-targeted activity-based probes. Nat Med 2009, 15:967-973.
23. Edgington L.E., Verdoes M., Bogyo M. Functional imaging of proteases: recent advances in the design and application of substrate-based and activity-based probes. Curr Opin Chem Biol 2011, 15:798-805.
24. Edgington L.E., Verdoes M., Ortega A., Withana N.P., Lee J., Syed S., Bachmann M.H., Blum G., Bogyo M. Functional imaging of legumain in cancer using a new quenched activity-based probe. J Am Chem Soc 2013, 135:174-182.
25. Kato D., Boatright K.M., Berger A.B., Nazif T., Blum G., Ryan C., Chehade K.A., Salvesen G.S., Bogyo M. Activity-based probes that target diverse cysteine protease families. Nat Chem Biol 2005, 1:33-38.
26. Lee J., Bogyo M. Development of near-infrared fluorophore (NIRF)-labeled activity-based probes for in vivo imaging of legumain. ACS Chem Biol 2010, 5:233-243.
27. Chang J.W., Moellering R.E., Cravatt B.F. An activity-based imaging probe for the integral membrane hydrolase KIAA1363. Angewandte Chemie 2012, 51:966-970.
28. Bachovchin D.A., Brown S.J., Rosen H., Cravatt B.F. Identification of selective inhibitors of uncharacterized enzymes by high-throughput screening with fluorescent activity-based probes. Nat Biotechnol 2009, 27:387-394.
29. Northen T.R., Lee J.C., Hoang L., Raymond J., Hwang D.R., Yannone S.M., Wong C.H., Siuzdak G. A nanostructure-initiator mass spectrometry-based enzyme activity assay. Proc Natl Acad Sci USA 2008, 105:3678-3683.
30. Greving M., Cheng X., Reindl W., Bowen B., Deng K., Louie K., Nyman M., Cohen J., Singh A., Simmons B., Adams P., Siuzdak G., Northen T. Acoustic deposition with NIMS as a high-throughput enzyme activity assay. Anal Bioanal Chem 2012, 403:707-711.
31. Medina-Cleghorn D., Nomura D.K. Chemical approaches to study metabolic networks. Pflugers Archiv: Eur J Physiol 2013, 465:427-440.
32. Li W., Blankman J.L., Cravatt B.F. A functional proteomic strategy to discover inhibitors for uncharacterized hydrolases. J Am Chem Soc 2007, 129:9594-9595.
33. Bachovchin D.A., Ji T., Li W., Simon G.M., Blankman J.L., Adibekian A., Hoover H., Niessen S., Cravatt B.F. Superfamily-wide portrait of serine hydrolase inhibition achieved by library-versus-library screening. Proc Natl Acad Sci USA 2010, 107:20941-20946.
34. Bachovchin D.A., Mohr J.T., Speers A.E., Wang C., Berlin J.M., Spicer T.P., Fernandez-Vega V., Chase P., Hodder P.S., Schurer S.C., Nomura D.K., Rosen H., Fu G.C., Cravatt B.F. Academic cross-fertilization by public screening yields a remarkable class of protein phosphatase methylesterase-1 inhibitors. Proc Natl Acad Sci USA 2011, 108:6811-6816.
35. Johnson D.S., Stiff C., Lazerwith S.E., Kesten S.R., Fay L.K., Morris M., Beidler D., Liimatta M.B., Smith S.E., Dudley D.T., Sadagopan N., Bhattachar S.N., Kesten S.J., Nomanbhoy T.K., Cravatt B.F., Ahn K. Discovery of PF-04457845: a highly potent, orally bioavailable, and selective urea FAAH inhibitor. ACS Med Chem Lett 2011, 2:91-96.
36. Ahn K., Smith S.E., Liimatta M.B., Beidler D., Sadagopan N., Dudley D.T., Young T., Wren P., Zhang Y., Swaney S., Van Becelaere K., Blankman J.L., Nomura D.K., Bhattachar S.N., Stiff C., Nomanbhoy T.K., Weerapana E., Johnson D.S., Cravatt B.F. Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. J Pharmacol Exp Ther 2011, 338:114-124.
37. Long J.Z., Li W., Booker L., Burston J.J., Kinsey S.G., Schlosburg J.E., Pavon F.J., Serrano A.M., Selley D.E., Parsons L.H., Lichtman A.H., Cravatt B.F. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 2009, 5:37-44.
38. Long J.Z., Nomura D.K., Vann R.E., Walentiny D.M., Booker L., Jin X., Burston J.J., Sim-Selley L.J., Lichtman A.H., Wiley J.L., Cravatt B.F. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci USA 2009, 106:20270-20275.
39. Ahn K., Johnson D.S., Mileni M., Beidler D., Long J.Z., McKinney M.K., Weerapana E., Sadagopan N., Liimatta M., Smith S.E., Lazerwith S., Stiff C., Kamtekar S., Bhattacharya K., Zhang Y., Swaney S., Van Becelaere K., Stevens R.C., Cravatt B.F. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol 2009, 16:411-420.
40. Chang J.W., Nomura D.K., Cravatt B.F. A potent and selective inhibitor of KIAA1363/AADACL1 that impairs prostate cancer pathogenesis. Chem Biol 2011, 18:476-484.
41. Bachovchin D.A., Cravatt B.F. The pharmacological landscape and therapeutic potential of serine hydrolases. Nat Rev Drug Discov 2012, 11:52-68.
42. Blankman J.L., Cravatt B.F. Chemical probes of endocannabinoid metabolism. Pharmacol Rev 2013, 65:849-871.
43. Mulvihill M.M., Nomura D.K. Therapeutic potential of monoacylglycerol lipase inhibitors. Life Sci 2013, 92:492-497.
44. Ahn K., McKinney M.K., Cravatt B.F. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 2008, 108:1687-1707.
45. Adibekian A., Martin B.R., Wang C., Hsu K.L., Bachovchin D.A., Niessen S., Hoover H., Cravatt B.F. Click-generated triazole ureas as ultrapotent in vivo-active serine hydrolase inhibitors. Nat Chem Biol 2011, 7:469-478.
46. Nomura D.K., Morrison B.E., Blankman J.L., Long J.Z., Kinsey S.G., Marcondes M.C., Ward A.M., Hahn Y.K., Lichtman A.H., Conti B., Cravatt B.F. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 2011, 334:809-813.
47. Piro J.R., Benjamin D.I., Duerr J.M., Pi Y., Gonzales C., Wood K.M., Schwartz J.W., Nomura D.K., Samad T.A. A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. Cell Rep 2012, 1:617-623.
48. Kinsey S.G., Long J.Z., O'Neal S.T., Abdullah R.A., Poklis J.L., Boger D.L., Cravatt B.F., Lichtman A.H. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther 2009, 330:902-910.
49. Long J.Z., LaCava M., Jin X., Cravatt B.F. An anatomical and temporal portrait of physiological substrates for fatty acid amide hydrolase. J Lipid Res 2011, 52:337-344.
50. Hsu K.L., Tsuboi K., Speers A.E., Brown S.J., Spicer T., Fernandez-Vega V., Ferguson J., Cravatt B.F., Hodder P., Rosen H. Optimization and characterization of a triazole urea inhibitor for diacylglycerol lipase beta (DAGL-beta). Probe Reports from the NIH Molecular Libraries Program, 2010.
51. Knuckley B., Jones J.E., Bachovchin D.A., Slack J., Causey C.P., Brown S.J., Rosen H., Cravatt B.F., Thompson P.R. A fluopol-ABPP HTS assay to identify PAD inhibitors. Chem Commun 2010, 46:7175-7177.
52. Saghatelian A., Cravatt B.F. Discovery metabolite profiling-forging functional connections between the proteome and metabolome. Life Sci 2005, 77:1759-1766.
53. Vinayavekhin N., Homan E.A., Saghatelian A. Exploring disease through metabolomics. ACS Chem Biol 2010, 5:91-103.
54. Saghatelian A., McKinney M.K., Bandell M., Patapoutian A., Cravatt B.F. A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. Biochemistry 2006, 45:9007-9015.
55. Chiang K.P., Niessen S., Saghatelian A., Cravatt B.F. An enzyme that regulates ether lipid signaling pathways in cancer annotated by multidimensional profiling. Chem Biol 2006, 13:1041-1050.
56. Cao Z., Mulvihill M.M., Mukhopadhyay P., Xu H., Erdelyi K., Hao E., Holovac E., Hasko G., Cravatt B.F., Nomura D.K., Pacher P. Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice. Gastroenterology 2013, 144. 808-817 e815.
57. Costola-de-Souza C., Ribeiro A., Ferraz-de-Paula V., Calefi A.S., Aloia T.P., Gimenes-Junior J.A., de Almeida V.I., Pinheiro M.L., Palermo-Neto J. Monoacylglycerol Lipase (MAGL) inhibition attenuates acute lung injury in mice. PLoS One 2013, 8:e77706.
58. Kinsey S.G., Nomura D.K., O'Neal S.T., Long J.Z., Mahadevan A., Cravatt B.F., Grider J.R., Lichtman A.H. Inhibition of monoacylglycerol lipase attenuates nonsteroidal anti-inflammatory drug-induced gastric hemorrhages in mice. J Pharmacol Exp Ther 2011, 338:795-802.
59. Blankman J.L., Long J.Z., Trauger S.A., Siuzdak G., Cravatt B.F. ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC. Proc Natl Acad Sci USA 2013, 110:1500-1505.
60. Parsons D.W., Jones S., Zhang X.S., Lin J.C.H., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz L.A., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K.N., Shinjo S.M.O., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. An integrated genomic analysis of human glioblastoma Multiforme. Science 2008, 321:1807-1812.
61. Mardis E.R., Ding L., Dooling D.J., Larson D.E., McLellan M.D., Chen K., Koboldt D.C., Fulton R.S., Delehaunty K.D., McGrath S.D., Fulton L.A., Locke D.P., Magrini V.J., Abbott R.M., Vickery T.L., Reed J.S., Robinson J.S., Wylie T., Smith S.M., Carmichael L., Eldred J.M., Harris C.C., Walker J., Peck J.B., Du F.Y., Dukes A.F., Sanderson G.E., Brummett A.M., Clark E., McMichael J.F., Meyer R.J., Schindler J.K., Pohl C.S., Wallis J.W., Shi X.Q., Lin L., Schmidt H., Tang Y.Z., Haipek C., Wiechert M.E., Ivy J.V., Kalicki J., Elliott G., Ries R.E., Payton J.E., Westervelt P., Tomasson M.H., Watson M.A., Baty J., Heath S., Shannon W.D., Nagarajan R., Link D.C., Walter M.J., Graubert T.A., DiPersio J.F., Wilson R.K., Ley T.J. Recurring mutations found by sequencing an acute myeloid leukemia genome. New Engl J Med 2009, 361:1058-1066.
62. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., Marks K.M., Prins R.M., Ward P.S., Yen K.E., Liau L.M., Rabinowitz J.D., Cantley L.C., Thompson C.B., Heiden M.G.V., Su S.M. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-752.
63. Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., Li Y.S., Bhagwat N., Vasanthakumar A., Fernandez H.F., Tallman M.S., Sun Z.X., Wolniak K., Peeters J.K., Liu W., Choe S.E., Fantin V.R., Paietta E., Lowenberg B., Licht J.D., Godley L.A., Delwel R., Valk P.J.M., Thompson C.B., Levine R.L., Melnick A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
64. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.H., Ito S., Yang C., Wang P., Xiao M.T., Liu L.X., Jiang W.Q., Liu J., Zhang J.Y., Wang B., Frye S., Zhang Y., Xu Y.H., Lei Q.Y., Guan K.L., Zhao S.M., Xiong Y. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
65. Ulanovskaya O.A., Zuhl A.M., Cravatt B.F. NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nat Chem Biol 2013, 9:300-306.
66. Shyh-Chang N., Locasale J.W., Lyssiotis C.A., Zheng Y., Teo R.Y., Ratanasirintrawoot S., Zhang J., Onder T., Unternaehrer J.J., Zhu H., Asara J.M., Daley G.Q., Cantley L.C. Influence of threonine metabolism on S-adenosylmethionine and histone methylation. Science 2013, 339:222-226.
67. Munger J., Bajad S.U., Coller H.A., Shenk T., Rabinowitz J.D. Dynamics of the cellular metabolome during human cytomegalovirus infection. PLoS Pathog 2006, 2:e132.
68. Vastag L., Koyuncu E., Grady S.L., Shenk T.E., Rabinowitz J.D. Divergent effects of human cytomegalovirus and herpes simplex virus-1 on cellular metabolism. PLoS Pathog 2011, 7:e1002124.
69. Grady S.L., Purdy J.G., Rabinowitz J.D., Shenk T. Argininosuccinate synthetase 1 depletion produces a metabolic state conducive to herpes simplex virus 1 infection. Proc Natl Acad Sci USA 2013, 110:E5006-E5015.
70. Rabinowitz J.D., Purdy J.G., Vastag L., Shenk T., Koyuncu E. Metabolomics in drug target discovery. Cold Spring Harb Symp Quant Biol 2011, 76:235-246.